Last reviewed · How we verify
NCT04630184: SPA-VR
A Virtual Reality Exposure Intervention on Social Physical Anxiety in Women With Obesity
NA trial testing Exposure intervention in virtual reality in Obesity in 45 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | Universite du Quebec en Outaouais |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 September 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Exposure intervention in virtual reality
- Exercise
- Placebo
Conditions studied
- Obesity — all drugs for Obesity →
- Exercise — all drugs for Exercise →
- Virtual Reality — all drugs for Virtual Reality →
Sponsor
Universite du Quebec en Outaouais
Who can join
Adults 18 to 45, female only, with Obesity or Exercise. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of the project are to: i) assess the feasibility and acceptability of the protocol and the VR exposure intervention in women with obesity, and ii) obtain an estimate of the effect of VR exposure intervention associated with an exercise training on SPA, compliance, adherence and persistence to the exercise training, as well as persistence in PA practice in the middle term to calculate the sample size for a future larger randomized controlled trial (RCT) in women with obesity. A RCT of feasibility will be carried out. Forty-five women with obesity and a high level of SPA will be randomized into one of the following three groups: 1) Exercice and VR exposure (Ex + expo), 2) Exercise and psychological intervention control (Ex + control) or 3) waiting list (WL). The interventions will have a physical exercise training (identical for all) and a psychology intervention (different according to the condition: VR exposure or control). The feasibility and acceptability of the protocol and the VR exposure intervention will be assessed at the end of the study. SPA, PA practice, anthropometry, internalization of weight bias, body appreciation, perceived pleasure, motivational regulation, self-efficacy, affects as well as perception effort will be evaluated with questionnaires and scales validated before and after the intervention and 6 months after the end of the intervention. Sociodemographic data, depressive symptoms, problematic eating behaviors and propensity to immersion will be assessed during the initial visit only. Adherence, adherence and persistence to the PA program will be calculated at the end of the intervention. Persistence in PA practice will be calculated using data collected immediately after the end of the intervention and 6 months after the intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Validation of a Virtual Environment to Induce State Social Physique Anxiety in Women with Obesity and Social Physique Anxiety.
Jeanningros A, Baillot A, Corno G, Rivard MC, et al · · 2023 · cited 3× · PMID 37763006 · DOI 10.3390/jcm12186065
Verify or expand the search:
- PubMed search for NCT04630184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Universite du Quebec en Outaouais trials
Trials by the same sponsor.
- NCT06573905 — Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA · not yet recruiting
- NCT06282133 — Behavioural Experiments for Generalized Anxiety in Adolescents - Pilot Study · NA · unknown
- NCT04348617 — Effect of Acute Exercise on Food Intake and Energy Expenditure Following a Gastric Bypass · NA · unknown
- NCT03433625 — 6-Session Treatment for Generalized Anxiety Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04630184 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universite du Quebec en Outaouais
- Last refreshed: 3 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing